Type
Business expansion
Country
Denmark
Region
Location of affected unit(s)
Copenhagen, Kalundborg
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.20 - Manufacture of pharmaceutical preparations

1,000 jobs
Number of planned job creations
Job creation
Announcement Date
4 March 2014
Employment effect (start)
1 April 2014
Foreseen end date

Description

The Danish based MNC in pharmaceutical products, Novo Nordisk, plans to create 1,000 new jobs during 2014 of which 300 will be production jobs. This was reported by the union of the potential new workers, United Federation of Danish Workers, 3F, on the 4 March 2014. 

Around 100 of the new jobs will be at the production site in Kalundborg in West Zealand. Other jobs will be created in Copenhagen. Novo Nordisk mainly produces insulin and has 16,025 employees in Denmark as of March 2014.

The Novo Nordisk facility at Kalundborg is part of a well-known eco-industrial complex involving many other plants. 


Sources

  • 5 March 2014: Avisen
  • 4 March 2014: 3F.DK

Citation

Eurofound (2014), Novo Nordisk, Business expansion in Denmark, factsheet number 76719, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/76719.